[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

Measures to tackle anticancer chemotherapy-induced nausea and vomiting in patients with recurrent advanced breast cancer are of great importance to the continuation of anticancer chemotherapy and to the improvement of patient quality of life. The present study designed as a randomized crossover comparison was carried out to evaluate the efficacy of granisetron in the prevention of anticancer chemotherapy-induced nausea and vomiting in comparison with methylprednisolone.
A questionnaire investigation was carried out in 33 patients who received anticancer chemotherapy at the Department of Surgery II of Tokyo Women's Medical College from January 1994 to January 1995, in order to evaluate the efficacy of the 2 kinds of antiemetic agent in the prevention of nausea, vomiting, anorexia, and malaise as adverse reactions to anticancer chemotherapy (with CEF or epirubicin alone).
1. Granisetron was more effective in the treatment of nausea in its acute stage than methylprednisolone, and the difference in efficacy was statistically significant (p=0.024).
2. The frequency of vomiting was significantly lower after administration of granisetron than after administration of methylprednisolone in a certain time zone (p=0.040), but generally there appeared to be no difference between the granisetron and the methylprednisolone groups regarding the frequency of vomiting.
3. The severity of anorexia in its acute stage was significantly lower after administration of granisetron than after administration of methylprednisolone (p=0.014).
4. Judging from the subjective patient assessment, granisetron exhibited a greater antiemetic effect than did methylprednisolone.
In this study, granisetron was shown to be more effective than was methylprednisolone in the prevention of anticancer chemotherapy-induced nausea and vomiting in patients with recurrent advanced breast cancer. Based on these results, granisetron seems to promise to do much towards the improvement of patient quality of life.

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract

[in Japanese]

View full abstract